Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Hepatology|March 1, 1997
Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis CT Goeser, S Seipp, R Wahl, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 11, 1998
Incidence, prevalence, and clinical outcome of hepatitis GB-C virus infection in liver transplant patientsB Kallinowski, C Buhrmann, S Seipp, et al.
Zeitschrift Fur Gastroenterologie|December 3, 2003
Fulminant liver failure induced by hepatosplenic alphabeta T-cell lymphomaC Petersen-Benz, N Hoffmann, T Beckurts, et al.
Archives of Virology. Supplementum|January 1, 1992
Follow-up of patients with hepatitis non-A, non-B: incidence and persistence of anti-HCV depend on route of transmissionK Gmelin, F Kurzen, B Kallinowski, et al.
Infection|July 8, 2000
Hepatitis virus-related and ethanol-induced chronic liver disease with or without cryoglobulins--is there a difference concerning clinical or laboratory manifestation?B Breitschwerdt, T Goeser, J D Tissot, et al.
Journal of Hepatology|April 20, 1999
Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell linesS Seipp, M Scheidel, W J Hofmann, et al.
European Journal of Clinical Investigation|August 1, 1992
Role of hepatitis C virus infection in German patients with fulminant and subacute hepatic failureL Theilmann, C Solbach, U Toex, et al.
Der Internist|November 10, 2019
[Abdominal pain and unclear focal liver lesion in 46-year-old female patient]P Kasper, B Holzapfel, R Whaba, et al.
Presse Medicale (Paris, France : 1983)|April 7, 1994
Prevalence and serological manifestation of hepatitis C virus infection in patients with hepatitis non-A, non-B: a follow-up studyT Goeser, H M Müller, C Solbach, et al.
Zeitschrift Fur Gastroenterologie|April 28, 2001
Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infectionB Kallinowski, H Liehr, B Moeller, et al.
Pageof 5